Randal Scott
BridgeBio PharmaAbout Randal W. Scott
Randal W. Scott, Ph.D., age 67, is an independent director of BridgeBio Pharma (BBIO) serving since June 2020. He holds a B.S. in Chemistry from Emporia State University and a Ph.D. in Biochemistry from the University of Kansas, and is currently Chairman and CEO of Genomic Life (since January 2024) . He is a member of BBIO’s Audit Committee and the Board has determined he is independent under Nasdaq and SEC rules; in 2024, all directors met at least 75% attendance across Board and committee meetings .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Genomic Life | Chairman & CEO | Jan 2024–present | Leadership in genomics business |
| Invitae Corporation | Chairman & CEO; Executive Chairman; Director | CEO 2012–2017; Exec Chair 2017–2019; Director 2010–Aug 2019; Rejoined as Chairman Jul 2022–Aug 2024 | Built and led genetic testing company |
| Genomic Health, Inc. | Co‑founder; Chairman & CEO; Executive Chairman | CEO 2000–2009; Exec Chair 2009–2012 | Founder; oncology diagnostics expertise |
External Roles
| Organization | Role | Since | Notes |
|---|---|---|---|
| Talis Biomedical (Nasdaq: TLIS) | Director | Feb 2016 | Molecular diagnostics board service |
| Freenome Holdings, Inc. | Director | N/A | Early cancer detection; private company board |
| Genomic Life | Chairman & CEO | Jan 2024 | Operating role; see Past Roles |
Board Governance
- Committee assignments: Audit Committee member; Audit chaired by Andrea Ellis; Aguiar/Ellis designated as Audit Committee financial experts .
- Independence: Board determined all directors except Kumar, Homcy, McCormick are independent; Scott is independent .
- Attendance: Board met 9 times in 2024; all directors met ≥75% combined Board/committee attendance; 9 directors attended the 2024 annual meeting .
- Board structure: Staggered board; Scott is Class I, serving until the 2026 annual meeting .
Fixed Compensation (Director)
| Item | 2024 Amount | Vesting/Terms |
|---|---|---|
| Annual cash retainer (Board membership) | $50,000 | No meeting or committee fees |
| Annual non‑statutory stock option grant | $549,998 grant date fair value | 10‑year term; vests in three equal annual installments; exercise price = grant date close; accelerated on “sale event” under 2021 Plan |
| Total 2024 director compensation (Scott) | $599,998 | $50,000 cash + $549,998 options |
Performance Compensation (Director)
- Director equity is time‑based; no disclosed performance metrics (e.g., TSR, revenue) tied to director awards. Annual options vest in three equal annual tranches over 3 years; accelerated on “sale event” if awards are not assumed .
Other Directorships & Interlocks
| Entity | Type | Position | Potential Interlock/Notes |
|---|---|---|---|
| Talis Biomedical (TLIS) | Public | Director | No BBIO related‑party transactions disclosed with Scott/Talis |
| Freenome Holdings | Private | Director | No related‑party exposure disclosed |
| Invitae | Public (historical) | Former Chairman/CEO; Director | Prior roles; no current BBIO related‑party exposure disclosed |
| Genomic Life | Private | Chairman & CEO | Operating role; no BBIO related‑party exposure disclosed |
- Note: BBIO’s Compensation Committee includes Ali Satvat of KKR, a >5% holder via KKR Genetic Disorder L.P.; Audit Committee screens related party transactions. No Scott‑specific related party transactions disclosed in 2024 .
Expertise & Qualifications
- Scientific and operating credentials building genomics/biotech companies (Genomic Health, Invitae, Genomic Life) .
- Audit Committee membership indicates governance involvement, though not designated an SEC “financial expert” (designation held by Aguiar and Ellis) .
- Education: B.S. Chemistry (Emporia State); Ph.D. Biochemistry (University of Kansas) .
Equity Ownership
| Metric | Detail |
|---|---|
| Total beneficial ownership | 236,232 shares (9,000 common + 227,232 vested/exercisable options within 60 days of Apr 1, 2025) |
| Ownership as % of outstanding | <1% (BBIO had 189,856,023 shares outstanding as of Apr 1, 2025) |
| Outstanding options held (as of 12/31/2024) | 322,554 options outstanding |
| Vested vs. unvested (near‑term) | 227,232 options vested/exercisable within 60 days (balance unvested) |
| Direct shareholding entities | 5,000 shares by Dr. Scott; 4,000 via Thinking Bench Capital LLC (manager: Scott; The OG Family Trust sole member) |
| Hedging/pledging | Company prohibits hedging and pledging by insiders; no pledging by Scott disclosed |
Insider Trades (Form 4)
| Date | Type | Shares | Price | Value | Holding After | Source |
|---|---|---|---|---|---|---|
| 2024‑06‑03 | Sale | 2,500 | $30.32 | $75,793 | 9,000 | |
| 2024‑03‑01 | Sale | 2,500 | $34.00 | $85,000 | 11,500 | |
| 2023‑12‑18 | Sale | 2,000 | $40.00 | $80,000 | 14,000 | |
| 2023‑12‑01 | Sale | 2,500 | $29.40 | $73,500 | 16,000 | |
| 2023‑09‑05 | Sale | 2,500 | $30.00 | $75,000 | 18,500 | |
| 2021‑02‑17 | Purchase | 16,000 | $62.50 | $1,000,000 | 21,000 | |
| 2025‑06‑20 | Option award | 15,014 | $0 (grant) | N/A | 24,014 (direct) |
Note: BBIO grants annual director option awards (e.g., Form 4 option grant filed June 24, 2025 for 6/20/2025) . Insider trading policy prohibits hedging/pledging .
Governance Assessment
- Alignment: Director pay structure is modest cash ($50k) with substantial equity via time‑based options, creating equity exposure over three years; accelerated vesting only on sale events per plan, which is typical and shareholder‑protective .
- Independence & Oversight: Scott is independent and serves on the Audit Committee; Audit members meet enhanced independence standards and oversee financial reporting, related party review, and enterprise risk items beyond financial risk (including cybersecurity and clinical/regulatory) .
- Ownership & Signals: Beneficial ownership shows options comprise most exposure (227k vested/exercisable; 9k common). Multiple small open‑market sales in 2023–2024 suggest personal liquidity rather than a structural misalignment; he also made a $1.0M open‑market purchase in 2021, indicating prior commitment .
- Conflicts & Related Parties: No Scott‑specific related party transactions disclosed; BBIO’s Audit Committee reviews related person transactions; broader related party items disclosed pertain to other directors (e.g., consulting) and are overseen by Audit . KKR’s board representative sits on the Compensation Committee and KKR is a >5% holder, but no Scott linkage to KKR .
- RED FLAGS: None apparent specific to Scott—no pledging, no hedging; attendance thresholds met; compensation structure standard for BBIO directors. Monitor ongoing external operating role (Genomic Life) for any future related‑party transactions or competitive overlaps; none disclosed to date .
Citations: and Internet sources as provided above.